KR101790257B1 - 마크롤라이드 면역억제제 약물을 포함하는 신규한 약제학적 조성물 - Google Patents

마크롤라이드 면역억제제 약물을 포함하는 신규한 약제학적 조성물 Download PDF

Info

Publication number
KR101790257B1
KR101790257B1 KR1020127009028A KR20127009028A KR101790257B1 KR 101790257 B1 KR101790257 B1 KR 101790257B1 KR 1020127009028 A KR1020127009028 A KR 1020127009028A KR 20127009028 A KR20127009028 A KR 20127009028A KR 101790257 B1 KR101790257 B1 KR 101790257B1
Authority
KR
South Korea
Prior art keywords
component
pharmaceutical formulation
tacrolimus
composition
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127009028A
Other languages
English (en)
Korean (ko)
Other versions
KR20120093865A (ko
Inventor
알렉산드라 자비네 베어벨 괴벨
Original Assignee
노바리크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바리크 게엠베하 filed Critical 노바리크 게엠베하
Publication of KR20120093865A publication Critical patent/KR20120093865A/ko
Application granted granted Critical
Publication of KR101790257B1 publication Critical patent/KR101790257B1/ko
Assigned to 스키노믹스 게엠베하 reassignment 스키노믹스 게엠베하 권리의 전부이전등록 Assignors: 노이베르트, 라인하르트, 볼랍, 요하네스
Assigned to 노이베르트, 라인하르트, 볼랍, 요하네스 reassignment 노이베르트, 라인하르트 권리의 전부이전등록 Assignors: 노바리크 게엠베하
Assigned to 베이 파마 게엠베하 reassignment 베이 파마 게엠베하 권리의 전부이전등록 Assignors: 스키노믹스 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • G01N2001/4061—Solvent extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020127009028A 2009-10-08 2010-10-07 마크롤라이드 면역억제제 약물을 포함하는 신규한 약제학적 조성물 Active KR101790257B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09012724A EP2308468A1 (en) 2009-10-08 2009-10-08 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
EP09012724.2 2009-10-08
PCT/EP2010/064965 WO2011042485A1 (en) 2009-10-08 2010-10-07 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug

Publications (2)

Publication Number Publication Date
KR20120093865A KR20120093865A (ko) 2012-08-23
KR101790257B1 true KR101790257B1 (ko) 2017-10-26

Family

ID=41435414

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127009028A Active KR101790257B1 (ko) 2009-10-08 2010-10-07 마크롤라이드 면역억제제 약물을 포함하는 신규한 약제학적 조성물

Country Status (12)

Country Link
US (1) US8574562B2 (https=)
EP (2) EP2308468A1 (https=)
JP (1) JP5764792B2 (https=)
KR (1) KR101790257B1 (https=)
CN (1) CN102510752B (https=)
AU (1) AU2010305404B2 (https=)
BR (1) BR112012007332B1 (https=)
CA (1) CA2774720C (https=)
ES (1) ES2552803T3 (https=)
IN (1) IN2012DN01559A (https=)
MX (1) MX2012003800A (https=)
WO (1) WO2011042485A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
WO2012176865A1 (ja) * 2011-06-23 2012-12-27 参天製薬株式会社 ヒアルロン酸またはその塩およびプロピレングリコールを含有する点眼液
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
CN103830178B (zh) * 2014-03-18 2017-01-11 深圳劲创生物技术有限公司 一种蒜氨酸微乳及其制备方法和应用
RU2737893C2 (ru) * 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением
JP6932180B2 (ja) * 2016-04-04 2021-09-08 エムシー２・セラピューティクス・リミテッドＭＣ２ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ タクロリムスを含む局所組成物
KR20190016036A (ko) * 2016-06-03 2019-02-15 아벡신 에이에스 다중불포화 케톤 및 칼시뉴린 억제제를 포함하는 조합 치료요법
CN106074386A (zh) * 2016-08-31 2016-11-09 佛山市弘泰药物研发有限公司 一种依维莫司自微乳制剂及其制备方法
EP3515422A1 (en) 2016-09-21 2019-07-31 Avexxin AS Pharmaceutical composition
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CA3124945A1 (en) 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
CA3164846A1 (en) * 2020-01-22 2021-07-29 Nayan Desai Topical compositions comprising a macrolide immunosuppressant
TWI769745B (zh) * 2021-03-19 2022-07-01 國泰醫療財團法人國泰綜合醫院 醫藥組成物與製藥用途
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
BE1030538B1 (nl) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan
KR102727647B1 (ko) * 2023-11-28 2024-11-08 장병모 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062334A1 (en) * 2004-12-06 2006-06-15 Hanmi Pharm. Co., Ltd. Oral micro-emulsion composition comprising tacrolimus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2315216B (en) * 1993-10-05 1998-10-14 Ciba Geigy Ag Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin
ATE299017T1 (de) * 1994-10-26 2005-07-15 Novartis Pharma Gmbh Arzneimittel
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
IL161588A0 (en) * 2001-11-01 2004-09-27 Yissum Res Dev Co Method and composition for dry eye treatment
HUP0402318A3 (en) * 2001-12-14 2012-09-28 Jagotec Ag Pharmaceutical composition comprising cyclosporin and use thereof
AU2005263551B2 (en) * 2004-07-16 2009-04-09 Novartis Ag Use of a steroid for enhancement of skin permeability
EP1929996B1 (en) * 2004-11-09 2011-02-16 Novagali Pharma S.A. Ophthalmic emulsions containing an immunosuppressive agent
EP1848407A2 (en) * 2005-02-02 2007-10-31 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062334A1 (en) * 2004-12-06 2006-06-15 Hanmi Pharm. Co., Ltd. Oral micro-emulsion composition comprising tacrolimus

Also Published As

Publication number Publication date
US20120184511A1 (en) 2012-07-19
KR20120093865A (ko) 2012-08-23
IN2012DN01559A (https=) 2015-06-05
EP2485714A1 (en) 2012-08-15
CN102510752A (zh) 2012-06-20
CA2774720A1 (en) 2011-04-14
ES2552803T3 (es) 2015-12-02
BR112012007332A2 (pt) 2016-10-04
AU2010305404B2 (en) 2015-04-02
WO2011042485A1 (en) 2011-04-14
JP5764792B2 (ja) 2015-08-19
CN102510752B (zh) 2015-08-05
AU2010305404A1 (en) 2012-03-08
JP2013507337A (ja) 2013-03-04
BR112012007332B1 (pt) 2021-07-13
EP2308468A1 (en) 2011-04-13
US8574562B2 (en) 2013-11-05
CA2774720C (en) 2017-05-23
MX2012003800A (es) 2012-06-28
EP2485714B1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
KR101790257B1 (ko) 마크롤라이드 면역억제제 약물을 포함하는 신규한 약제학적 조성물
US12115255B2 (en) Methods of use of emulsion formulations of an NK-1 receptor antagonist
US20200197404A1 (en) Emulsion formulations of aprepitant
JP2960867B2 (ja) 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法
EP3411013A1 (en) Emulsion comprising an nk-1 receptor antagonist
CZ302649B6 (cs) Farmaceutická formulace zahrnující cyklosporin a její použití
KR20230054682A (ko) Jak 저해제 및 라우레스-4를 함유하는 국소 제형
WO2006098241A1 (ja) 難水溶性薬物を含有する医薬組成物
US20190231688A1 (en) Method of administering emulsion formulations of an nk-1 receptor antagonist
HK1167102A (en) Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
EP3917498B1 (en) Self-emulsifying pharmaceutical composition in the liquid form, containing as the active substance a drug substance unstable in an aqueous environment

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151007

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161018

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170719

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20171019

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20171020

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211007

Start annual number: 5

End annual number: 5